Tatva Chintan Q1: consolidated PAT more than doubles to ₹16 Cr, revenue up 43% YoY

Tatva Chintan Pharma Chem opened FY27 with a decisively strong quarter. Consolidated revenue from operations rose 42.9% YoY to ₹167.1 Cr (up 24.5% sequentially) and consolidated PAT jumped 140% YoY to ₹15.98 Cr, with basic EPS at ₹6.83 versus ₹2.84 a year ago. Net margin expanded to 9.6% from 5.6% a year earlier and 7.7% last quarter — the profit growth ran well ahead of revenue, driven by operating leverage on a higher topline. Notably, the reported profit absorbs a ₹1.32 Cr exceptional loss (unexplained in the notes) that was absent last year; excluding it, underlying PAT is ~₹17.3 Cr, or roughly +160% YoY — so the headline understates the operating improvement rather than flattering it. Against management's own FY27 guidance of ~25% revenue growth with 20-22% EBITDA margins, the print beats comfortably on growth (Q1 revenue +43% YoY) but sits marginally below the margin band — estimated operating margin was ~19.3%, a touch under the 20-22% target and softer than last quarter's 21%, worth watching as the raw-material pass-through story management flagged plays out. The bullish, confident tone from the Q4 concall is confirmed by these numbers. On street expectations, no specific quarterly consensus estimate surfaced; available analyst coverage (Univest, May-26) carries a 12-month price target of ~₹1,200 with Q1 flagged as the key confirmation checkpoint — a bar this print clears on growth. Consolidated substantially outpaces standalone: standalone PAT was ₹10.45 Cr (+103% YoY) on ₹146.7 Cr revenue, meaning the wholly-owned US and Europe subsidiaries contributed a material share of the group's growth — readers comparing the two numbers should note the ~37-point growth gap reflects subsidiary strength, not an error in either figure. The same board meeting paired the result with two growth-capital actions: approval of a new greenfield capacity addition at Dahej-III (aggregate reactor capacity of 344 KL, ~₹200 Cr capex over ~21 months, funded via internal accruals and debt) and a hike in the borrowing limit from ₹300 Cr to ₹1,000 Cr. Together with the MD/whole-time director re-appointments, this signals the company is gearing its balance sheet for the next capacity-led leg management has been guiding toward.